Back to Portfolio


Lifesaving liver disease medicines

Versantis is a Biotech company developing breakthrough liver disease treatments and diagnostics addressing high unmet medical needs.

Its lead candidate, VS-01, is currently at preclinical stage and has the potential to be the first treatment for acute liver disease, simultaneously supporting multiple failing organs. VS-01 targets three rare indications and received orphan drug status. In addition, Versantis’ pipeline promises to improve patients’ outcome in other medical fields; VS-02 and VS-03 are developed for chronic liver diseases and for the treatment of drug intoxications, both representing large market opportunities.


Homepage LinkedIn Twitter  


Versantis in the News:

Versantis CEO featured on Insight Success

Four Redalpine Companies among the Top 30 Swiss Start-Ups

Versantis secures FDA orphan drug designation for first product

Redalpine leads Series A for health-tech company Versantis